Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Axsome Malta Drug Patent Portfolio

Axsome Malta owns 1 orange book drug protected by 36 US patents Given below is the list of Axsome Malta's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11771666 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US11771667 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US11779554 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US11793776 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US11872203 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US11872204 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US12005036 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US12036194 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US12064411 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US12090126 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US12102609 Methods of administering solriamfetol to lactating women 30 Dec, 2042
Active
US10940133 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11160779 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11839598 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11839599 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11850226 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11850227 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11850228 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11857528 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11969404 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11986454 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11986455 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
Active
US11560354 Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof 06 Mar, 2039
Active
US10912754 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
Active
US10959976 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
Active
US11648232 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
Active
US11865098 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
Active
US10195151 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
Active
US10512609 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
Active
US11439597 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
Active
US11998639 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
Active
US8440715 Treatment of sleep-wake disorders 11 Jun, 2031
Active
US10351517 Treatment of sleep-wake disorders 07 Jun, 2026
Active
US11753368 Treatment of sleep-wake disorders 07 Jun, 2026
Active
US8877806 Treatment of sleep-wake disorders 07 Jun, 2026
Active
US9604917 Treatment of sleep-wake disorders 07 Jun, 2026
Active


Given below is the list of recent legal activities going on the following drug patents of Axsome Malta.

Activity Date Patent Number
Patent litigations
Mail Patent eCofC Notification 28 May, 2024 US11969404
Patent eCofC Notification 28 May, 2024 US11969404
Recordation of Patent eCertificate of Correction 28 May, 2024 US11969404
Email Notification
Critical
28 May, 2024 US11969404
Mail Patent eCofC Notification 21 May, 2024 US11771667
Patent eCofC Notification 21 May, 2024 US11771667
Email Notification
Critical
21 May, 2024 US11771667
Recordation of Patent eCertificate of Correction 21 May, 2024 US11771667
Change in Power of Attorney (May Include Associate POA)
Critical
03 May, 2024 US8877806
Email Notification
Critical
03 May, 2024 US8877806
Email Notification
Critical
30 Apr, 2024 US11969404
Recordation of Patent Grant Mailed
Critical
30 Apr, 2024 US11969404
Mail Patent eGrant Notification 30 Apr, 2024 US11969404
Patent eGrant Notification 30 Apr, 2024 US11969404
Recordation of Patent eGrant 30 Apr, 2024 US11969404


Axsome Malta's Family Patents

Axsome Malta drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 38.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Axsome Malta Drug List

Given below is the complete list of Axsome Malta's drugs and the patents protecting them.


1. Sunosi

Sunosi is protected by 36 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11771666 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US11771667 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US11779554 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US11793776 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US11872203 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US11872204 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US12005036 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US12036194 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US12064411 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US12090126 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US12102609 Methods of administering solriamfetol to lactating women 30 Dec, 2042
(18 years from now)
Active
US10940133 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11160779 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11839598 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11839599 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11850226 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11850227 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11850228 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11857528 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11969404 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11986454 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11986455 Methods of providing solriamfetol therapy to subjects with impaired renal function 19 Mar, 2040
(15 years from now)
Active
US11560354 Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof 06 Mar, 2039
(14 years from now)
Active
US10912754 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
(13 years from now)
Active
US10959976 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
(13 years from now)
Active
US11648232 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
(13 years from now)
Active
US11865098 Methods and compositions for treating excessive sleepiness 01 Jun, 2038
(13 years from now)
Active
US10195151 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
(12 years from now)
Active
US10512609 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
(12 years from now)
Active
US11439597 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
(12 years from now)
Active
US11998639 Formulations of (R)-2-amino-3-phenylpropyl carbamate 05 Sep, 2037
(12 years from now)
Active
US8440715 Treatment of sleep-wake disorders 11 Jun, 2031
(6 years from now)
Active
US10351517 Treatment of sleep-wake disorders 07 Jun, 2026
(1 year, 6 months from now)
Active
US11753368 Treatment of sleep-wake disorders 07 Jun, 2026
(1 year, 6 months from now)
Active
US8877806 Treatment of sleep-wake disorders 07 Jun, 2026
(1 year, 6 months from now)
Active
US9604917 Treatment of sleep-wake disorders 07 Jun, 2026
(1 year, 6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sunosi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List